Epigallocatechin-3-Gallate
Prevention & Control
Shandong Cancer Hospital and InstitutePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Prevention & Control cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Bayer | Phase 3 | BB |
BAY 59-7939 Bayer | Phase 3 | BB |
Rivaroxaban Bayer | Phase 3 | BB |
PANTOPRAZOLE Bayer | Phase 3 | B |
Same molecule, other indications
Epigallocatechin-3-Gallate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →